ReviewApplied microbiology and biotechnology2022
Current view on novel vaccine technologies to combat human infectious diseases.
Review in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Encapsulation of the lipidated TLR7/8 agonist INI-4001 into ionic liposomes impacts H7 influenza antigen-specific immune responses.Drug delivery and translational research · 2026Article
- Delivery Systems of mRNA Vaccines in the Treatment of Infectious Diseases: From Lipid Nanoparticles to Next-Generation Platforms.Advanced pharmaceutical bulletin · 2025Review
- Article
- Development of an efficacious oral peptide vaccine against infection with the carcinogenic liver fluke Opisthorchis viverrini.Vaccine · 2025Article
- Biogenic gold nanoparticles synthesized using3 Biotech · 2025Article
- Mpox virus (MPXV): comprehensive analysis of pandemic risks, pathophysiology, treatments, and mRNA vaccine development.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Design and Preliminary Immunogenicity Evaluation of Nipah Virus Glycoprotein G Epitope-Based Peptide Vaccine in Mice.Vaccines · 2025Article
- Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model.Iranian journal of basic medical sciences · 2025Article
- Astragalus Polysaccharide Nanoemulsion: A Promising Adjuvant for Foot-And-Mouth Disease Virus-Like Particle Vaccines.Transboundary and emerging diseases · 2025Article
- Progress in combination vaccines and the co-administration of influenza virus and SARS-CoV-2 vaccines.Frontiers in immunology · 2025Review
- Beyond Needles: Immunomodulatory Hydrogel-Guided Vaccine Delivery Systems.Gels (Basel, Switzerland) · 2024Review
- Exploring advanced genomic and immunoinformatics techniques for identifying drug and vaccine targets against SARS-CoV-2.Journal, genetic engineering & biotechnology · 2024Article
- Developing a potent vaccine againstExpert reviews in molecular medicine · 2024Review
- Nanoparticles as Delivery Systems for Antigenic Saccharides: From Conjugation Chemistry to Vaccine Design.Vaccines · 2024Review
- Lipid A-modified Escherichia coli can produce porcine parvovirus virus-like particles with high immunogenicity and minimal endotoxin activity.Microbial cell factories · 2024Article
- Putative new combination vaccine candidates identified by reverse vaccinology and genomic approaches to control enteric pathogens.BMC immunology · 2024Article
- Antimicrobial resistance containment in Africa: Moving beyond surveillance.Biosafety and health · 2024Review
- Nanotechnology in the Diagnosis and Treatment of Antibiotic-Resistant Infections.Antibiotics (Basel, Switzerland) · 2024Review
- Future Prospects, Approaches, and the Government's Role in the Development of a Hepatitis C Virus Vaccine.Pathogens (Basel, Switzerland) · 2023Review
- An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines.Biomolecules · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Inactivated and live attenuated vaccines have improved human life and significantly reduced morbidity and mortality of several human infectious diseases. However, these vaccines have faults, such as reactivity or suboptimal efficacy and expensive and time-consuming development and production. Additionally, despite the enormous efforts to develop vaccines against some infectious diseases, the traditional technologies have not been successful in achieving this. At the same time, the concerns about emerging and re-emerging diseases urge the need to develop technologies that can be rapidly applied to combat the new challenges. Within the last two decades, the research of vaccine technologies has taken several directions to achieve safe, efficient, and economic platforms or technologies for novel vaccines. This review will give a brief overview of the current state of the novel vaccine technologies, new vaccine candidates in clinical trial phases 1-3 (listed by European Medicines Agency (EMA) and Food and Drug Administration (FDA)), and vaccines based on the novel technologies which have already been commercially available (approved by EMA and FDA) with the special reference to pandemic COVID-19 vaccines. KEY POINTS: • Vaccines of the new generation follow the minimalist strategy. • Some infectious diseases remain a challenge for the vaccine development. • The number of new vaccine candidates in the late phase clinical trials remains low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.